Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 10/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | BCL6 | P41182 | 1/20 | 0.40 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191669 | 0.89 | DYRK1A (0.46) | DYRK1ACDK7KDM4EGAAMKNK1 | |
| SCHEMBL22191607 | 0.85 | FYN (0.54) | CDK7CDK2KDM4EGAAFYN | |
| SCHEMBL22191078 | 0.84 | VNN1 (0.54) | DYRK1ACDK7VNN1CDK2MKNK1 | |
| SCHEMBL22191227 | 0.84 | PDE3B (0.47) | CDK7CDK2KDM4EGAAMKNK2 | |
| SCHEMBL22191602 | 0.83 | GAA (0.48) | DYRK1AKDM4EGAAFYN | |
| SCHEMBL22191838 | 0.83 | CCNT1 (0.48) | DYRK1ACDK2KDM4EGAACLK1 | |
| SCHEMBL4190030 | 0.82 | FYN (0.60) | DYRK1ACDK7VNN1CDK2MKNK1 | |
| SCHEMBL29664810 | 0.82 | GAA (0.45) | CDK7CDK2KDM4EGAAMKNK1 | |
| SCHEMBL22191151 | 0.81 | BCL6 (0.48) | DYRK1ACDK2KDM4ECLK1BCL6 | |
| SCHEMBL22191218 | 0.80 | GAA (0.52) | DYRK1AKDM4EGAACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| EP-3906233-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113508111-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142485-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | DYRK1A 481/4885CDK7 120/4885VNN1 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.